These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. In vitro efficacy of known P-glycoprotein modulators compared to droloxifene E and Z: studies on a human T-cell leukemia cell line and their resistant variants. Nüssler V; Pelka-Fleisc R; Gieseler F; Hasmann M; Löser R; Gullis E; Stötzer O; Zwierzina H; Wilmanns W Leuk Lymphoma; 1998 Nov; 31(5-6):589-97. PubMed ID: 9922050 [TBL] [Abstract][Full Text] [Related]
4. Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies. Sonneveld P Eur J Cancer; 1996 Jun; 32A(6):1062-9. PubMed ID: 8763348 [No Abstract] [Full Text] [Related]
5. Diagnosis and reversal of multidrug resistance in paediatric cancers. Chan HS; Grogan TM; DeBoer G; Haddad G; Gallie BL; Ling V Eur J Cancer; 1996 Jun; 32A(6):1051-61. PubMed ID: 8763347 [No Abstract] [Full Text] [Related]
6. Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study. González-Manzano R; Cid J; Brugarolas A; Piasecki CC Br J Cancer; 1995 Nov; 72(5):1294-9. PubMed ID: 7577485 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein. Starling JJ; Shepard RL; Cao J; Law KL; Norman BH; Kroin JS; Ehlhardt WJ; Baughman TM; Winter MA; Bell MG; Shih C; Gruber J; Elmquist WF; Dantzig AH Adv Enzyme Regul; 1997; 37():335-47. PubMed ID: 9381979 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological considerations in the modulation of multidrug resistance. Fisher GA; Lum BL; Hausdorff J; Sikic BI Eur J Cancer; 1996 Jun; 32A(6):1082-8. PubMed ID: 8763350 [No Abstract] [Full Text] [Related]
9. Synergistic effects of verapamil and anti-mdr1 ribozyme on reversion of multidrug resistance in the P-glycoprotein-positive K562 cell line. Gong Y; Han W; Liu J; Chen F; Han J; Jin Y; Yong RO Leukemia; 2001 Apr; 15(4):696-7. PubMed ID: 11368386 [No Abstract] [Full Text] [Related]
10. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers. Ford JM Eur J Cancer; 1996 Jun; 32A(6):991-1001. PubMed ID: 8763340 [No Abstract] [Full Text] [Related]
11. The reversal of multidrug resistance. Fisher GA; Lum BL; Sikic BI Cancer Treat Res; 1995; 78():45-70. PubMed ID: 8595147 [No Abstract] [Full Text] [Related]
12. In vivo models of P-glycoprotein-mediated multidrug resistance. Gottesman MM; Mickisch GH; Pastan I Cancer Treat Res; 1994; 73():107-28. PubMed ID: 7710902 [No Abstract] [Full Text] [Related]
14. Multidrug resistance: can new drugs help chemotherapy score against cancer? Goldman B J Natl Cancer Inst; 2003 Feb; 95(4):255-7. PubMed ID: 12591977 [No Abstract] [Full Text] [Related]
15. Effect of some P-glycoprotein modulators on Rhodamine-123 absorption in guinea-pig ileum. Colabufo NA; Berardi F; Contino M; Inglese C; Niso M; Perrone R Bioorg Med Chem Lett; 2008 Jul; 18(13):3741-4. PubMed ID: 18524592 [TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance reversal in childhood malignancies--potential for a real step forward? Pinkerton CR Eur J Cancer; 1996 Apr; 32A(4):641-4. PubMed ID: 8695268 [No Abstract] [Full Text] [Related]
17. What have we learnt thus far from mice with disrupted P-glycoprotein genes? Borst P; Schinkel AH Eur J Cancer; 1996 Jun; 32A(6):985-90. PubMed ID: 8763339 [No Abstract] [Full Text] [Related]
18. Multidrug resistance: P-glycoprotein and its allies--the elusive foes. Chabner BA; Fojo A J Natl Cancer Inst; 1989 Jun; 81(12):910-3. PubMed ID: 2567356 [No Abstract] [Full Text] [Related]
19. Recent advances in the development of P-gp inhibitors. Baumert C; Hilgeroth A Anticancer Agents Med Chem; 2009 May; 9(4):415-36. PubMed ID: 19442042 [TBL] [Abstract][Full Text] [Related]